Hoechst AG and Rhone-Poulenc S.A. merged their life sciences businesses to create Aventis, then one of the world's largest pharmaceutical companies with combined revenue of approximately $20 billion. The merger was implemented through an exchange offer with Hoechst shareholders receiving Rhone-Poulenc shares at a 4:3 ratio.